Subscribe To
RDUS / Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer
RDUS News
By Seeking Alpha
October 18, 2023
Radius Recycling: Holding After The Rebrand
Radius Recycling has experienced management and a strong balance sheet, but there are risks related to commodity prices, the strength of the dollar, a more_horizontal
By Benzinga
May 20, 2022
Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer
The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or meta more_horizontal
By Zacks Investment Research
March 1, 2022
Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet
The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal
By Zacks Investment Research
March 1, 2022
Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet
The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal
By Zacks Investment Research
March 1, 2022
Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet
The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is more_horizontal
By Zacks Investment Research
February 25, 2022
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal
By Zacks Investment Research
February 25, 2022
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal
By Zacks Investment Research
February 25, 2022
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. more_horizontal